FDA Antidepressant Safety Plan Includes "Black Box," Unit-Of-Use Packaging
This article was originally published in The Pink Sheet Daily
Executive Summary
Unit-of-use packaging will ensure distribution of patient MedGuides, FDA says. Agency asks all antidepressant manufacturers to add "black box" warning, as recommended by advisory committee in September.
You may also be interested in...
CDER’s Neurology Division Prepares For New Leadership With Director Katz’s Retirement
Russell Katz will retire following a 30-year career at FDA; his departure comes as the agency is embarking on new efforts to encourage drug development for Alzheimer’s disease and amyotrophic lateral sclerosis.
FDA Psychiatry Division To Be Headed By Laughren Under Restructuring Plan
Neuropharmacological reviewer Laughren will head FDA's psychiatric drug reviews after the division is spun off under the Office of New Drugs reorganization. Laughren's appointment is one of few top-level promotions under the restructuring effort.
FDA Psychiatry Division To Be Headed By Laughren Under Restructuring Plan
Neuropharmacological reviewer Laughren will head FDA's psychiatric drug reviews after the division is spun off under the Office of New Drugs reorganization. Laughren's appointment is one of few top-level promotions under the restructuring effort.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: